News

Filter

Current filters:

Gastro-intestinalsShire

1 to 9 of 12 results

Actavis prevails in Lialda patent dispute in USA

Actavis prevails in Lialda patent dispute in USA

31-03-2014

US generics major Actavis says that the US Court of Appeals for the Federal Circuit has reversed a lower…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsShireUSA

Shire prevails in US Lialda patent dispute with Watson

10-05-2013

Ireland-headquartered drugmaker Shire's (LSE: SHP) subsidiary Shire Development has prevailed in its…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsPharmaceuticalShireWatson Pharmaceuticals

Shire takes hit as bowel disease drug Lialda fails in Ph III trial

02-04-2012

The shares of Ireland-headquartered Shire (LSE: SHP) dropped 4.9% to £20.14 in mid afternoon trading…

Gastro-intestinalsLialdaMesalaminePharmaceuticalResearchShire

Shire gets US Rights to Resolor

10-01-2012

Ireland-headquartered specialty biopharma firm Shire (LSE: SHP) says that it has acquired the rights…

Gastro-intestinalsMarkets & MarketingMergers & AcquisitionsNorth AmericaPharmaceuticalResolorShire

Shire’s Lialda now OKed for ulcerative colitis maintenance of remission in the USA

19-07-2011

The US Food and Drug Administration has approved Ireland-headquartered specialty drugmaker Shire’s…

Gastro-intestinalsLialdaNorth AmericaPharmaceuticalRegulationShire

Highlights from Digestive Disease Week

11-05-2011

The 2011 Digestive Disease Week meeting in Chicago, USA, heard a number of interesting presentations…

Abbott LaboratoriesDificidGastro-intestinalsJohnson & JohnsonLubiprostoneOptimer PharmaceuticalsPharmaceuticalRemicadeResearchResolorShireStelara InjectionSucampo

Shire says 2nd-qtr 2010 revenues rose 35% and EPS leapt 71%; updates on Firazyr; Movetis’ Resolor cleared in Switzerland

05-08-2010

UK specialty drugmaker Shire, which has moved its headquarters to Ireland for tax reasons, posted rocketing…

BiotechnologyFinancialFirazyrGastro-intestinalsMovetisPharmaceuticalRare diseasesRegulationResearchResolorShire

Shire buying Movetis for $558 million to expand specialist gastrointestinal portfolio

04-08-2010

Dublin, Ireland-based specialty biopharmaceutical company Shire revealed yesterday that it will launch…

Gastro-intestinalsGeneralMergers & AcquisitionsMovetisPharmaceuticalResolorShire

1 to 9 of 12 results

Back to top